Mashup Score:2100
JAMA NetworkEpidemiology and Outcomes of SARS-CoV-2 or MISC vs Influenza Among Critically Ill Children - 2 days
Mashup Score:2100
Twitter Feed: American Thoracic
Mashup Score:2095
JAMA NetworkEpidemiology and Outcomes of SARS-CoV-2 or MISC vs Influenza Among Critically Ill Children - 1 week
Mashup Score:2095
This cohort study compares the epidemiology and outcomes of patients in the pediatric intensive care unit with SARS-CoV-2–related disease during the first 15 months...
-
#COVID19 poses far more danger to kids than seasonal flu: https://t.co/TgjvV22yI2 #vaccineswork - view on twitter
Mashup Score:172
NatureRapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR – Nature Biotechnology - 1 week
Mashup Score:172
The T cell response to SARS-CoV-2 is detected by a PCR assay on whole...
-
Newly developed blood test may help measure #COVID19 immunity: https://t.co/sgatTqgrWz - view on twitter
More coverage:
#covid19
Mashup Score:66
New England Journal of Medicine (NEJM)Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5 | NEJM - 3 days
Mashup Score:66
Correspondence from The New England Journal of Medicine — Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and...
-
Data suggest #omicron subvariants BA.4 and BA.5 appear to evade antibody responses induced by vaccination, prior infection: https://t.co/W7NTJTGPv5 - view on twitter
More coverage:
#omicron
PURPOSE Lorlatinib significantly improved progression-free survival (PFS) versus crizotinib and showed robust intracranial activity in patients with previously untreated advanced ALK-positive non–small-cell lung cancer...
-
Patients with previously untreated advanced ALK-positive #NSCLC experienced better outcomes with first-line lorlatinib versus crizotinib: https://t.co/X5S4S9bUfm - view on twitter
More coverage:
#nsclc
Mashup Score:29
www.thoracic.orgFDA Removes Juul from U.S. Market – An Important, But Temporary, Decision - 7 days
Mashup Score:29
American Thoracic...
-
Thank you @US_FDA for removing #Juul products from the U.S. marketplace. Removing them, even temporarily, will make a small but important dent in sales to school-age kids. Read our statement here: https://t.co/yJJWShfGBA - view on twitter
More coverage:
#juul
Mashup Score:13
www.thoracic.orgATS Fellow - 3 days
Mashup Score:13
American Thoracic...
-
Are you ready to become an ATS Fellow? The application period closes on August 31, 2022. Learn more: https://t.co/pFNR4IKEbb - view on twitter
The role of extracorporeal membrane oxygenation (ECMO) in the management of severe acute respiratory failure, including acute respiratory distress syndrome, has become better defined...
-
Read “#ECMO during Respiratory Pandemics: Past, Present, and Future,” for an outline of lessons learned during #COVID19 and prior respiratory pandemics in which ECMO was used, and how these lessons might be applied going forward: https://t.co/K90vUZMGKF #openaccess https://t.co/K90vUZMGKF - view on twitter
Mashup Score:8
www.thoracic.orgGrant Resource Guide - 6 days
Mashup Score:8
American Thoracic...
-
Great resource! Find the ATS MITT Committee Grant Resource Guide here: https://t.co/M5BsKtOK3j https://t.co/M5BsKtOK3j - view on twitter
Mashup Score:8
ThoraxTelerehabilitation for chronic respiratory disease: a randomised controlled equivalence trial - 1 week
Mashup Score:8
Rationale Pulmonary rehabilitation is an effective treatment for people with chronic respiratory disease but is delivered...
-
Join @PR_Assembly on June 28 at 5PM ET for Journal Club on the article Telerehabilitation for chronic respiratory disease (https://t.co/UZPSYb9G1X). Register here: https://t.co/UZPSYb9G1X). https://t.co/UZPSYb9G1X). - view on twitter
This cohort study compares the epidemiology and outcomes of patients in the pediatric intensive care unit with SARS-CoV-2–related disease during the first 15 months...
#COVID19 poses far more danger to kids than seasonal flu: https://t.co/TgjvV22yI2 #vaccineswork - view on twitter